English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

of results We analyzed 2,892 patients with median age of 32 years; 2,055 (71%) women; 1,569 (54%) WHO stage 3; 974 (34%) anaemia; 472 (16%) low BMI; and 1,242 (43%) with CD4 counts <200 cells/μl. WHO stage 3 compared to WHO stages 1 and 2 had sensitivity and specificity (95% CI) of 70% (67, 72) and 57% (55, 60), respectively, to detect CD4 counts <200 cells/μl. Anaemia had sensitivity and specificity (95% CI) of 47% (44, 50) and 76% (74, 78), respectively. Low BMI had sensitivity and specificity (95% CI) of 23% (20, 25) and 89% (87, 90), respectively, against CD4 counts <200 cells/μl. WHO stage 3 or anaemia or low BMI had sensitivity and specificity (95% CI) of 79% (77, 81) and 50% (47, 52), respectively. Conclusion Only WHO stage 3 had an acceptable sensitivity to identify patients with CD4 counts of <200 cells/μl in this setting; whilst specificity was modest. Other screening strategies such as on-site low-cost CD4 testing need to be developed to identify patients in need of HAART in rural Africa and other resource-limited settings. from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008

Evaluating affordable screening markers to detect HIV-1-infected Ugandan adults with CD4 counts of less than 200 cells/mul